论文部分内容阅读
目的:探讨多潘立酮联合伊托必利治疗功能性消化不良的临床疗效和安全性。方法:服用多潘立酮联合伊托必利治疗的63例功能性消化不良患者为观察组,服用多潘立酮治疗的60例功能性消化不良患者为对照组,比较两组患者治疗前后食欲不振、上腹痛、餐后不适等消化不良症状情况和临床疗效。结果:观察组治疗有效率为92.06%,显著高于对照组(58.33%);经治疗后,全部患者总症状积分和临床症状均明显改善(P<0.05),观察组总症状积分和上腹痛、餐后不适、食欲不振等临床症状的评分均明显低于对照组(P<0.05);两组药物不良反应比较差异无显著性(P>0.05)。结论:多潘立酮联合伊托必利治疗功能性消化不良的临床疗效更佳,安全性高,值得临床推广使用。
Objective: To investigate the clinical efficacy and safety of domperidone and itopride in the treatment of functional dyspepsia. Methods: Sixty-three patients with functional dyspepsia treated with domperidone combined with itopride were selected as the observation group. Sixty patients with functional dyspepsia treated with domperidone as the control group. The patients in both groups were compared for appetite loss, upper abdominal pain, After discomfort and other symptoms and clinical symptoms of dyspepsia. Results: The effective rate of observation group was 92.06%, which was significantly higher than that of control group (58.33%). After treatment, the total symptom scores and clinical symptoms of all patients were significantly improved (P <0.05) , Postprandial discomfort, loss of appetite and other clinical symptoms were significantly lower than the control group (P <0.05); two groups of drug adverse reactions was no significant difference (P> 0.05). Conclusion: The clinical efficacy of domperidone and itopride in the treatment of functional dyspepsia is better and the safety is higher. It is worth to be used clinically.